Gossamer Bio, Inc. 8-K

What Happened
Gossamer Bio, Inc. (GOSS) filed an 8‑K on April 9, 2026 reporting that on April 8, 2026 it received a written notice from Nasdaq’s Listing Qualifications Staff that its common stock failed to maintain the $1.00 minimum bid price for the 30 consecutive business day period from February 24, 2026 through April 7, 2026. Nasdaq’s notice does not cause immediate delisting; the Company has a 180‑calendar‑day compliance period under Nasdaq Rule 5810(c)(3)(A) to cure the deficiency.

Key Details

• Notice received: April 8, 2026; 8‑K filed April 9, 2026.
• Noncompliance period: Feb 24, 2026 – Apr 7, 2026 (30 consecutive business days).
• Cure requirement: closing bid ≥ $1.00 for at least 10 consecutive business days before the compliance deadline (Compliance Date: Oct 5, 2026).
• If not cured, the Company may seek an additional 180‑day period by transferring to the Nasdaq Capital Market and meeting its listing standards (other than the minimum bid), or pursue other actions such as a reverse stock split; Nasdaq staff will review and could issue a delisting notice, which the Company could appeal.

Why It Matters
A continued failure to meet the $1.00 minimum bid could lead to delisting from Nasdaq, which can reduce liquidity, limit investor access, and affect institutional ownership. Gossamer Bio says it will monitor the stock price and consider options to regain compliance, but there is no assurance it will succeed. Investors should watch the stock’s closing price and any corporate actions (e.g., reverse split) or Nasdaq correspondence for developments.